Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ACE | P12821 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5674353 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2ACEMAPTTAAR1THRB | |
| SCHEMBL9773201 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2ACEMAPTTAAR1THRB | |
| SCHEMBL10957115 | 0.90 | KMT2A (0.39) | SMN1; SMN2ACEMAPTHTTHSD17B10 | |
| SCHEMBL7722450 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2ACEMAPTMMP8PPARG | |
| SCHEMBL20676404 | 0.89 | ACE (0.37) | SMN1; SMN2ACEMAPTHTTHSD17B10 | |
| SCHEMBL7375987 | 0.88 | BLM (0.41) | BLMPPARGPPARAL3MBTL1 | |
| SCHEMBL5012826 | 0.88 | BLM (0.41) | BLMPPARGPPARAL3MBTL1 | |
| SCHEMBL8142297 | 0.88 | MEN1 (0.43) | SMN1; SMN2BLMPPARGPPARA | |
| SCHEMBL7344531 | 0.88 | BLM (0.41) | BLMPPARGPPARAL3MBTL1 | |
| SCHEMBL7728941 | 0.88 | MEN1 (0.43) | SMN1; SMN2BLMPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261166-B2 | Lipophilic macrocyclic ligands, complexes thereof, and uses of same | GUERBET (FR) | 2022-03-01 | — | — | US | disclosed |
| CN-109438449-B | Synthesis method of cilazapril containing hexahydropyridazine acid structure | 厦门医学院 | 2020-08-11 | — | — | CN | disclosed |
| US-20200231554-A1 | LIPOPHILIC MACROCYCLIC LIGANDS, COMPLEXES THEREOF, AND USES OF SAME | GUERBET (FR) | 2020-07-23 | — | — | US | disclosed |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2005009972-A2 | PROCESS FOR PREPARATION OF BENAZEPRIL | RANBAXY LABORATORIES LIMITED (IN) | 2005-02-03 | — | — | WO | disclosed |
| US-5231084-A | ACE inhibitor | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-27 | — | — | US | disclosed |
| US-5043346-A | Amino acid esters, pharmaceuticals containing them, and the use thereof in learning disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-27 | — | — | US | disclosed |
| US-4857520-A | Fused azepinone and azocinone derivatives, processes for their preparation, agents containing them and their use, and intermediates in their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-15 | — | — | US | disclosed |
| US-4831051-A | CALCIUM ANTAGONIST; ANTIARRHYTHMIA, HYPOTENSIVE AND CARDIOTONIC AGENTS; VASODILATION | DELANDE S.A. (FR) | 1989-05-16 | — | — | US | disclosed |
| US-4801721-A | Stereospecific synthesis of carboxyalkyl peptides | RYAN JAMES W (US) | 1989-01-31 | — | — | US | disclosed |
| US-4732896-A | ANTAGONIST TO CALCIUM | DELALANDE S.A. (FR) | 1988-03-22 | — | — | US | disclosed |
| EP-0186431-B1 | ANTI-HYPERTENSIVE OCTAHYDRO-6-AZAINDOLE DIPEPTIDE DERIVATIVES | Pfizer Limited (GB) | 1988-02-03 | — | — | EP | disclosed |
| US-4711882-A | INHIBITOR OF ANGIOTENSIN CONVERTING ENZYME; HYPOTENSIVE AND CARDIOTONIC AGENTS | PFIZER INC. (US) | 1987-12-08 | — | — | US | disclosed |
| EP-0186431-A1 | Anti-hypertensive octahydro-6-azaindole dipeptide derivatives | Pfizer Limited (GB) | 1986-07-02 | — | — | EP | disclosed |
| US-4536500-A | ANTAGONISTIC ACTIVITY TO CALCIUM | DELALANDE S.A. (FR) | 1985-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261166-B2 | Lipophilic macrocyclic ligands, complexes thereof, and uses of same | LDLR, NPC1L1, LRP6 | SMN1; SMN2 4820/4885ACE 2969/4885MAPT 3931/4885 |
| US-20200231554-A1 | LIPOPHILIC MACROCYCLIC LIGANDS, COMPLEXES THEREOF, AND USES OF SAME | LDLR, NPC1L1, LRP6 | SMN1; SMN2 4820/4885ACE 2969/4885MAPT 3931/4885 |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | SMN1; SMN2 2869/4885ACE 3665/4885MAPT 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.